Refine Results
  1. "Mark Kris"
Formats
  1. Journal Article (350)
  2. Meeting Abstract (239)
  3. Book Section (7)
  4. Conference Paper (2)
Groups
  1. Solid Tumor Oncology Division (598)
  2. Thoracic Malignancies Disease Management Team (598)
  3. Thoracic Oncology Service (598)
  4. Thoracic Oncology (435)
  5. Thoracic Oncology (163)
  6. Human Oncology and Pathogenesis Program (151)

More Groups

People
  1. Mark Kris (598)
  2. Vincent Miller (166)
  3. Gregory Riely (157)
  4. Marc Ladanyi (133)
  5. Valerie Rusch (103)
  6. Lee Krug (90)

More People

Years
  1. 2019 (6)
  2. 2018 (20)
  3. 2017 (20)
  4. 2016 (23)
  5. 2015 (42)
  6. 2014 (34)

More Years

Publications
  1. Journal of Clinical Oncology (150)
  2. Journal of Thoracic Oncology (96)
  3. Clinical Cancer Research (53)
  4. Lung Cancer (28)
  5. Cancer (25)
  6. Annals of Oncology (17)

More Publications

Publishers
  1. American Society of Clinical Oncology (156)
  2. Elsevier Inc. (121)
  3. American Association for Cancer Research (83)
  4. Elsevier Ireland Ltd. (29)
  5. Oxford University Press (28)
  6. Wiley Blackwell (27)

More Publishers

Results (598)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Tumor mutation burden and efficacy of EGFR-tyrosine kinase inhibitors in patients with EGFR-mutant lung cancers
    Journal Article

    Offin, M.; Rizvi, H.; Tenet, M.; Ni, A.; Sanchez-Vega, F.; Li, B. T.; Drilon, A.; Kris, M. G.; Rudin, C. M.; Schultz, N.; more...
    Clinical Cancer Research (2019)

    Fulltext@MSK | Save
  • Pathologic assessment after neoadjuvant chemotherapy for NSCLC: Importance and implications of distinguishing adenocarcinoma from squamous cell carcinoma
    Journal Article

    Qu, Y.; Emoto, K.; Eguchi, T.; Aly, R. G.; Zheng, H.; Chaft, J. E.; Tan, K. S.; Jones, D. R.; Kris, M. G.; Adusumilli, P. S.; more...
    Journal of Thoracic Oncology (2019)

    Fulltext@MSK | Save
  • Activation of KRAS mediates resistance to targeted therapy in MET exon 14–mutant non–small cell lung cancer
    Journal Article

    Suzawa, K.; Offin, M.; Lu, D.; Kurzatkowski, C.; Vojnic, M.; Smith, R. S.; Sabari, J. K.; Tai, H.; Mattar, M.; Khodos, I.; more...
    Clinical Cancer Research (2019)

    Fulltext@MSK | Save
  • SELECT: A phase II trial of adjuvant erlotinib in patients with resected epidermal growth factor receptor-mutant non-small-cell lung cancer
    Journal Article

    Pennell, N. A.; Neal, J. W.; Chaft, J. E.; Azzoli, C. G.; Jänne, P. A.; Govindan, R.; Evans, T. L.; Costa, D. B.; Wakelee, H. A.; Heist, R. S.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • Outcomes after neoadjuvant or adjuvant chemotherapy for cT2-4N0-1 non–small cell lung cancer: A propensity-matched analysis
    Journal Article

    Brandt, W. S.; Yan, W.; Zhou, J.; Tan, K. S.; Montecalvo, J.; Park, B. J.; Adusumilli, P. S.; Huang, J.; Bott, M. J.; Rusch, V. W.; more...
    Journal of Thoracic and Cardiovascular Surgery (2019)

    Fulltext@MSK | Save
  • Afatinib in patients with metastatic or recurrent HER2-mutant lung cancers: A retrospective international multicentre study
    Journal Article

    Lai, W. V.; Lebas, L.; Barnes, T. A.; Milia, J.; Ni, A.; Gautschi, O.; Peters, S.; Ferrara, R.; Plodkowski, A. J.; Kavanagh, J.; more...
    European Journal of Cancer (2019)

    Fulltext@MSK | Save
  • Molecular and imaging predictors of response to ado-trastuzumab emtansine in patients with HER2 mutant lung cancers: An exploratory phase 2 trial
    Meeting Abstract

    Li, B.; Offin, M.; Hembrough, T.; Cecchi, F.; Shen, R.; Olah, Z.; Panora, E.; Myers, M.; Brzostowski, E.; Buonocore, D.; more...
    Journal of Thoracic Oncology (2018)

    Fulltext@MSK | Save
  • MET exon 14-altered lung cancers: Central nervous system (CNS) metastases and patterns of CNS progression on MET inhibition
    Meeting Abstract

    Offin, M.; Dienstag, J.; Wilkins, O.; Sabari, J.; Ni, A.; Feldman, D.; Van Voorthuysen, M.; Suzawa, K.; Yu, H.; Riely, G.; more...
    Journal of Thoracic Oncology (2018)

    Fulltext@MSK | Save
  • Clinical and molecular characteristics of EGFR mutant lung cancers with concurrent TP53 and RB1 mutations
    Meeting Abstract

    Offin, M.; Tenet, M.; Shen, R.; Rekhtman, N.; Rizvi, H.; Hellmann, M.; Arcila, M.; Ladanyi, M.; Rudin, C.; Kris, M.; more...
    Journal of Thoracic Oncology (2018)

    Fulltext@MSK | Save
  • Neoadjuvant atezolizumab in resectable non-small cell lung cancer (NSCLC): Updated results from a multicenter study (LCMC3)
    Meeting Abstract

    Rusch, V.; Chaft, J.; Johnson, B.; Wistuba, I.; Kris, M.; Lee, J.; Bunn, P. Jr; Kwiatkowski, D.; Reckamp, K.; Finley, D.; more...
    Journal of Thoracic Oncology (2018)

    Fulltext@MSK | Save